Free Republic

Gilead Sciences' (GILD) Sovaldi is now projected to become the best-selling medicine of all time by several analysts. Sovaldi is the first in a new wave of Hep C treatments that promise better cure rates and a shorter treatment course. Some even forecast it would reach $9 billion or more in sales by 2017, at which level it would surpass Pfizer's (PFE) Lipitor and take the crown as the biggest-selling drug of all time. Analysts are trying to outdo each other with optimistic forecasts. According to ISI Group analyst Mark Schoenebaum, if prescriptions were to never grow again, that is...

Gilead Sciences, facing mounting criticism over the high price of its new hepatitis C pill Sovaldi, has offered to supply the medicine to Egypt at a 99 percent discount to the U.S. price. While the drug will still cost $900 for a 12-week course of treatment, that is a fraction of the $84,000 charged for a course of treatment in the United States. The high price tag in America prompted questions from U.S. lawmakers on Friday, after U.S. health insurers said they were seeking help from state health officials to foot the bill. Gilead said it was "pleased to have...